Gabrielle_20
2022-01-21
🥴
UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":630887677,"tweetId":"630887677","gmtCreate":1642775889577,"gmtModify":1642775889738,"author":{"id":3569531614182731,"idStr":"3569531614182731","authorId":3569531614182731,"authorIdStr":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>🥴</p></body></html>","htmlText":"<html><head></head><body><p>🥴</p></body></html>","text":"🥴","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630887677","repostId":1125663172,"repostType":4,"repost":{"id":"1125663172","kind":"news","pubTimestamp":1642774815,"share":"https://www.laohu8.com/m/news/1125663172?lang=&edition=full","pubTime":"2022-01-21 22:20","market":"us","language":"en","title":"UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125663172","media":"Seeking Alpha","summary":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from","content":"<html><head></head><body><p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).</p><p>Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, "we think the recent move hints at a return to fundamentals after a highly volatile '21."</p><p>Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.</p><p>"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing," Merle writes. "We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow," Merle writes.</p><p>She notes that the company's pipeline is also too early "to move the needle for shares in '22."</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS cuts BioNTech price target by 43% saying pandemic trade premium is fading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 22:20 GMT+8 <a href=https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares ...</p>\n\n<a href=\"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125663172","content_text":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, \"we think the recent move hints at a return to fundamentals after a highly volatile '21.\"Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.\"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing,\" Merle writes. \"We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow,\" Merle writes.She notes that the company's pipeline is also too early \"to move the needle for shares in '22.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":814,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/630887677"}
精彩评论